TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29159204

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonpegylated interferon (IFN)
Number of subjects: 71
Study: 29159457

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 468
Study: 29159458

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg/week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 4.0 mg/kg/week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined dosage groups (2.0 mg/kg/week and 4.0 mg/kg/week)
Number of subjects: 25
Study: 29159476

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) administered as part of the FOLFOX regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) dosage per kg lean body mass (LBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) dosage for hematological toxicities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 0
Study: 29159905

Group type: EXPERIMENTAL
Intervention: Ex vivo expanded autologous bone marrow-derived mesenchymal stem cells (MSCs)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Islet autotransplantation
Number of subjects: 3
Study: 29160240

Group type: EXPERIMENTAL
Intervention: ECoG-based BCI system using somatotopic control strategy; subjects trained to control BCI by modulating high-gamma activity from attempted arm and hand movements for less than 30 days.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ECoG-based BCI system with electrode coverage of somatosensory cortex.
Number of subjects: 3
Study: 29160301

Group type: EXPERIMENTAL
Intervention: Citalopram/Escitalopram treatment
Number of subjects: 2147
Study: 29160421

Group type: EXPERIMENTAL
Intervention: Multiparous women
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 120
Study: 29161241

Group type: EXPERIMENTAL
Intervention: Sunitinib (66.50 mg '4-weeks on/2-weeks off' schedule and 37.5 mg continuous daily dosing)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg continuous daily dosing)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Sunitinib (general)
Number of subjects: 237
Study: 29161279

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) on cfDNA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Number of subjects: 32
Study: 29161802

Group type: EXPERIMENTAL
Intervention: Short course CCRT
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Long course CCRT
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (surgery timing < 6 weeks)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (surgery timing 6-7 weeks)
Number of subjects: 300
Study: 29162063

Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgE
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgG
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CD4 T-cell count <100 cells/μl
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Not on anti-retroviral therapy at baseline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pulmonary x-ray findings
Number of subjects: 101
Study: 29162085

Group type: EXPERIMENTAL
Intervention: Individuals with LUTS
Number of subjects: 8284

Group type: COMPARATOR
Intervention: Individuals without LUTS
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Individuals with LUTS (all three ICS symptom groups)
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Increasing OAB severity
Number of subjects: 8284
Study: 29162134

Group type: EXPERIMENTAL
Intervention: Palbociclib (C1D1 for four 28-day cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anastrozole monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palbociclib-induced decrease in serum TK1
Number of subjects: 0
Study: 29162138

Group type: EXPERIMENTAL
Intervention: Image-guided intraarticular facet joint infiltration
Number of subjects: 50

Group type: COMPARATOR
Intervention: MRI features assessed (neuroforaminal stenosis grading, posterior disc height)
Number of subjects: 50
Study: 29162148

Group type: EXPERIMENTAL
Intervention: SMS intervention (15 one-directional health educative text messages and SMS reminders for their appointment over 10 months)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 700
Study: 29162340

Group type: EXPERIMENTAL
Intervention: Intensive arm (systolic BP target of <120 mmHg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard arm (systolic BP target of <140 mmHg)
Number of subjects: 9361
Study: 29162343

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 176
Study: 29162502

Group type: EXPERIMENTAL
Intervention: real rTMS (n=13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: sham rTMS (n=15)
Number of subjects: 28
Study: 29162557

Group type: EXPERIMENTAL
Intervention: Smartphone-based telemonitoring system in addition to usual care
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study: 29162610

Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Angiographic Diameter Stenosis (DS)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Vessel-oriented clinical end point (VOCE)
Number of subjects: 607
Study: 29162718

Group type: EXPERIMENTAL
Intervention: Fluticasone hydrofluoroalkane inhaled via pMDI with no delay between shaking and actuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro + transport samples with no delay between shaking and actuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delays between shaking and actuating the pMDI
Number of subjects: 0
Study: 29162997

Group type: EXPERIMENTAL
Intervention: Employer's knowledge of smoking and perceived negative impact of smoking on the company
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Company characteristics (white-collar vs. blue-collar)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Workplace smoke-free policy and perceived responsibility
Number of subjects: 100
Study: 29163136

Group type: EXPERIMENTAL
Intervention: Video game training (non-action video games) for 16 sessions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 75
Study: 29163840

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 49
Study: 29164129

Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 0
Study: 29164130

Group type: EXPERIMENTAL
Intervention: Innovative rehabilitation protocol (Gr2)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional rehabilitation protocol (Gr1)
Number of subjects: 67
Study: 29164179

Group type: EXPERIMENTAL
Intervention: Schroth physiotherapeutic scoliosis-specific exercises (PSSE) + standard of care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50
Study: 29164334

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (1 µg/kg) test before extubation
Number of subjects: 80
Study: 29164420

Group type: EXPERIMENTAL
Intervention: Comprehensive BRCA1/2 testing with written pre-test information and optional telephone genetic counseling
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Written pre-test information
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Streamlined process of pre-test information and genetic testing
Number of subjects: 818
Study: 29165227

Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA)
Number of subjects: 0
Study: 29165789

Group type: EXPERIMENTAL
Intervention: CAPABLE program
Number of subjects: 204

Group type: COMPARATOR
Intervention: Matched comparison group
Number of subjects: 204
Study: 29166203

Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Three-month follow-up referral
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Six-month functional disability (GOSE ≤ 6)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Intracranial pathology on ED head CT
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Amnesia (>30-minutes)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Amnesia (unknown duration)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Older age (per-year)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Part-time/unemployment
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: GCS < 15
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Prior history of seizures
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Increased education (per-year)
Number of subjects: 168
Study: 29166877

Group type: EXPERIMENTAL
Intervention: Patients with above median extracellular volume (ECV) on cardiac magnetic resonance (CMR) imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher ECV on CMR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients undergoing surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymptomatic MR cohort
Number of subjects: 0
Study: 29166878

Group type: EXPERIMENTAL
Intervention: Circulating microRNAs and SNPs analysis in a case-control study
Number of subjects: 21000

Group type: COMPARATOR
Intervention: Standard screening protocol
Number of subjects: 21000
Study: 29166901

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen prescription
Number of subjects: 194

Group type: COMPARATOR
Intervention: UCSD dyspnea scores
Number of subjects: 194
Study: 29167092

Group type: EXPERIMENTAL
Intervention: Dry needling, manual therapy, and exercise
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham dry needling, manual therapy, and exercise
Number of subjects: 76
Study: 29167192

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 29167744

Group type: EXPERIMENTAL
Intervention: Lottery-based incentive scheme for active travel to school (ATS); parents report ATS days via paper or SMS for a chance to win a £5 voucher
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometry (ActiGraph GT3X+) to monitor physical activity levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily parental ATS reports
Number of subjects: 0
Study: 29167745

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention using smartphones for nutrition and physical activity
Number of subjects: 40
Study: 29168107

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 107
Study: 29168229

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29169258

Group type: EXPERIMENTAL
Intervention: hs-cTnT (high-sensitivity cardiac troponin T)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: hs-cTnI (high-sensitivity cardiac troponin I)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: hs-cTn assays
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: hs-cTn concentrations in patients <60 years and ≥60 years
Number of subjects: 273
Study: 29169394

Group type: EXPERIMENTAL
Intervention: Physical activity (steps per day)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 194
Study: 29169396

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) diet for 16 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA) diet for 16 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: n-6 polyunsaturated fatty acids (PUFA) diet for 16 weeks
Number of subjects: 120
Study: 29169399

Group type: EXPERIMENTAL
Intervention: PReDicT Test guided treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 100
Study: 29169470

Group type: EXPERIMENTAL
Intervention: Approved alternative anticoagulation (argatroban, lepirudin, danaparoid)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Approved alternative anticoagulation
Number of subjects: 195
Study: 29169474

Group type: COMPARATOR
Intervention: Early cohort (1990-1999)
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Late cohort (2000-2009)
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 1953
Study: 29170088

Group type: EXPERIMENTAL
Intervention: Mifepristone (200mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites)
Number of subjects: 406
Study: 29170358

Group type: EXPERIMENTAL
Intervention: Children with congenital heart diseases (CHD)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Age-adjusted and gender-adjusted controls
Number of subjects: 496
Study: 29171941

Group type: EXPERIMENTAL
Intervention: Extracorporeal cellular therapy (ELAD) plus standard of care (SOC) for 3-5 days
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: ELAD
Number of subjects: 203
Study: 29173296

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) and Body Mass Index (BMI)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) and Waist Circumference (WC)
Number of subjects: 737
Study: 29173893

Group type: EXPERIMENTAL
Intervention: FoodforCare (FfC) meal service
Number of subjects: 637

Group type: COMPARATOR
Intervention: Traditional meal service (TMS)
Number of subjects: 637
Study: 29174300

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390
Study: 29174484

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment for 1 year or longer
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 440

Group type: COMPARATOR
Intervention: No glucocorticoid treatment or cumulative treatment duration of less than 1 month
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 440
Study: 29174546

Group type: EXPERIMENTAL
Intervention: Ledipasvir and Sofosbuvir (90 mg ledipasvir + 400 mg sofosbuvir, once daily for 12 weeks)
Number of subjects: 111
Study: 29174612

Group type: EXPERIMENTAL
Intervention: Antituberculosis treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ART started during the first month of follow-up
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Confirmed tuberculosis
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Young age
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: CD4 less than 10%
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Miliary features
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Elevated serum transaminases
Number of subjects: 266
Study: 29174789

Group type: EXPERIMENTAL
Intervention: Optical strategy
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Location-based strategy
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Simplified optical strategy
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Simplified or location-based strategy
Number of subjects: 1658
Study: 29174927

Group type: EXPERIMENTAL
Intervention: CT colonography (CTC)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 231
Study: 29174939

Group type: EXPERIMENTAL
Intervention: Computer-based screening and physician feedback algorithm
Number of subjects: 2038
Study: 29175885

Group type: EXPERIMENTAL
Intervention: Active Herts community physical activity programme including behaviour change technique booklet, regular consultations, booster phone call, motivational text messages, and signposting to 12 weeks of exercise classes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active Herts community physical activity programme with additional 12 weeks of free tailored exercise classes and optional exercise 'buddies'.
Number of subjects: 0
Study: 29175898

Group type: EXPERIMENTAL
Intervention: LGMD2N cohort with known mutations and novel mutations
Number of subjects: 12
Study: 29176494

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) dosing between birth and 6 months (average 1882 LU/kg per meal, range: 492-3727)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) dosing between 6 and 12 months (mean 1842 LU/kg per meal, range: 313-3612)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Use of proton pump inhibitors (PPIs) exclusively
Number of subjects: 205

Group type: COMPARATOR
Intervention: Higher PERT dosing strategy
Number of subjects: 205
Study: 29176887

Group type: EXPERIMENTAL
Intervention: Real-Time PCR (qPCR) testing for Chagas disease
Number of subjects: 302

Group type: COMPARATOR
Intervention: Retesting of clinical samples from Bolivian laboratory
Number of subjects: 302
Study: 29177052

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes with eGFR <60 mL/min/1.73 m²
Number of subjects: 43

Group type: COMPARATOR
Intervention: Type 1 diabetes without diabetic kidney disease
Number of subjects: 43
Study: 29177059

Group type: EXPERIMENTAL
Intervention: STEMI in men
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: STEMI in women
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: NSTEMI in men
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: NSTEMI in women
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: STEMI in women <60 years
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: NSTEMI in women <60 years
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: STEMI in men <60 years
Number of subjects: 51725

Group type: EXPERIMENTAL
Intervention: NSTEMI in men <60 years
Number of subjects: 51725
Study: 29177061

Group type: COMPARATOR
Intervention: General practitioners (GPs)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Rheumatologists
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 241
Study: 29177070

Group type: EXPERIMENTAL
Intervention: MIS416 treatment for 12 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MIS416 treatment
Number of subjects: 11
Study: 29177094

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic combined with dacarbazine (up to 24 doses of MAGE-A3 immunotherapeutic and eight doses of dacarbazine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic
Number of subjects: 48
Study: 29177452

Group type: EXPERIMENTAL
Intervention: Internet-based educational intervention including four educational sessions over 4 weeks and six 30-min class discussions over 3 months.
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group observed general sex education provided by the school.
Number of subjects: 456
Study: 29177471

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline subcutaneous adipocyte volume
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: WAT COL4A1 expression
Number of subjects: 82
Study: 29177486

Group type: EXPERIMENTAL
Intervention: GLP-1 0.7 pmol/kg/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 1.2 pmol/kg/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 and ROSE-010 (in vitro)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 0
Study: 29177645

Group type: EXPERIMENTAL
Intervention: Ledipasvir-Sofosbuvir for 8 weeks
Number of subjects: 126
Study: 29177699

Group type: EXPERIMENTAL
Intervention: BI 409306 at 25 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BI 409306 at 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BI 409306 at 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BI 409306
Number of subjects: 40
Study: 29177953

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sirolimus
Number of subjects: 28
Study: 29178102

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based chemotherapy
Number of subjects: 53
Study: 29178583

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (vertical gastroplasty, gastric banding, or gastric bypass)
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2018
Study: 29178600

Group type: EXPERIMENTAL
Intervention: Norepinephrine stimulation of in vitro BAT activity in adipocytes derived from human BAT.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UCP1 mRNA expression in human BAT biopsies.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ZIC1 mRNA expression in human BAT biopsies.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Correlation of UCP1 mRNA with age and BMI.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Correlation of ZIC1 mRNA with age and BMI.
Number of subjects: 16
Study: 29178853

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Presence of pleural plaques
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Asbestos exposure
Number of subjects: 1570
Study: 29179674

Group type: EXPERIMENTAL
Intervention: suPAR levels ≥3.00 ng/ml
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 120

Group type: COMPARATOR
Intervention: Age alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age + suPAR
Number of subjects: 120
Study: 29179681

Group type: EXPERIMENTAL
Intervention: Low flow extracorporeal CO (Abylcap®)
Number of subjects: 0
Study: 29179731

Group type: EXPERIMENTAL
Intervention: TACT trial
Number of subjects: 3151

Group type: COMPARATOR
Intervention: NCDR
Number of subjects: 3151
Study: 29179748

Group type: EXPERIMENTAL
Intervention: Thresholding analysis for quantification of bone marrow inflammatory edema
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thresholding analysis for the spine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thresholding analysis for the SI joints
Number of subjects: 41

Group type: COMPARATOR
Intervention: SPARCC scoring system
Number of subjects: 41
Study: 29179751

Group type: EXPERIMENTAL
Intervention: Proton therapy (45-50.4 GyE in 1.8 GyE fractions 5-6 times per week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 25